TD Cowen raised the firm’s price target on Twist Bioscience to $55 from $48 and keeps a Buy rating on the shares. The firm said its revised guide still seems conservative given early Express Genes traction, order growth and FOTF scaling and they expect beat and raises throughout 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST: